Ascendis Pharma A/S $ASND Position Lessened by Wellington Management Group LLP

Posted by Stanley Muller on Aug 30th, 2026

Wellington Management Group LLP reduced its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 30.5% in the second quarter, Holdings Channel.com reports. The institutional investor owned 1,548,636 shares of the biotechnology company’s stock after selling 679,997 shares during the period. Wellington Management Group LLP’s holdings in Ascendis Pharma A/S were worth $413,052,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in ASND. Dearborn Partners LLC acquired a new stake in Ascendis Pharma A/S in the second quarter worth $347,000. Public Employees Retirement System of Ohio boosted its holdings in shares of Ascendis Pharma A/S by 245.4% during the second quarter. Public Employees Retirement System of Ohio now owns 19,977 shares of the biotechnology company’s stock valued at $5,328,000 after acquiring an additional 14,193 shares during the period. Seven Fleet Capital Management LP grew its position in shares of Ascendis Pharma A/S by 114.8% during the first quarter. Seven Fleet Capital Management LP now owns 12,179 shares of the biotechnology company’s stock worth $2,786,000 after acquiring an additional 6,509 shares during the last quarter. Parallel Advisors LLC grew its position in shares of Ascendis Pharma A/S by 94.9% during the first quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock worth $70,000 after acquiring an additional 148 shares during the last quarter. Finally, Perceptive Advisors LLC grew its position in shares of Ascendis Pharma A/S by 41.6% during the first quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock worth $350,282,000 after acquiring an additional 450,000 shares during the last quarter.

Ascendis Pharma A/S News Summary

Here are the key news stories impacting Ascendis Pharma A/S this week:

Positive Sentiment: HC Wainwright initiated coverage of Ascendis Pharma with a Buy rating and a $345 price target, implying approximately 39% potential upside from the referenced share price. The bullish stance provides positive analyst support for ASND. HC Wainwright initiates coverage
Positive Sentiment: HC Wainwright analyst M. Kapoor projected Ascendis Pharma will earn $3.93 per share in fiscal 2026, broadly above the cited consensus estimate of $3.90, and expects quarterly EPS of $1.16 in Q3 2026 and $1.66 in Q4 2026. HC Wainwright FY2026 estimates
Positive Sentiment: The firm forecast substantial earnings growth in 2027, with quarterly EPS estimates rising from $1.76 in Q1 to $4.42 in Q4, resulting in projected full-year EPS of $11.88. If achieved, that would represent a significant improvement over the 2026 forecast and supports the analyst’s optimistic valuation. HC Wainwright FY2027 estimates

Ascendis Pharma A/S Stock Performance

ASND stock opened at $247.91 on Friday. The company has a 50-day simple moving average of $255.74 and a 200 day simple moving average of $239.08. The company has a market capitalization of $15.46 billion, a P/E ratio of 19.23 and a beta of 0.39. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. Ascendis Pharma A/S has a fifty-two week low of $186.05 and a fifty-two week high of $282.15.

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last released its earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The company had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Sell-side analysts predict that Ascendis Pharma A/S will post 3.9 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ASND shares. HC Wainwright began coverage on shares of Ascendis Pharma A/S in a research report on Thursday. They issued a “buy” rating and a $345.00 price objective on the stock. Jefferies Financial Group restated a “buy” rating and issued a $333.00 target price on shares of Ascendis Pharma A/S in a research report on Thursday, August 13th. Royal Bank Of Canada raised their price target on shares of Ascendis Pharma A/S from $280.00 to $290.00 and gave the company an “outperform” rating in a research note on Friday, August 14th. Wall Street Zen raised Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, Weiss Ratings upgraded Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $302.68.

View Our Latest Stock Report on Ascendis Pharma A/S

Insider Activity

In related news, Director Jean Jacques Bienaime acquired 2,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was acquired at an average cost of $246.33 per share, for a total transaction of $492,660.00. Following the completion of the acquisition, the director directly owned 2,900 shares of the company’s stock, valued at approximately $714,357. The trade was a 222.22% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 40.00% of the stock is owned by company insiders.

Ascendis Pharma A/S Company Profile

(Free Report)

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.